PSUSA/00000227/202511
Submitted by Anonymous (not verified) on 14 July 2026 - 13:39
PSUSA/00000227/202511
PSUSA/00003167/202512
Submitted by Anonymous (not verified) on 14 July 2026 - 13:38
PSUSA/00003167/202512
PRIME eligibility requests: 2027 deadlines for submission and timetable for assessment
Submitted by Anonymous (not verified) on 14 July 2026 - 13:31
PRIME eligibility requests: 2027 deadlines for submission and timetable for assessment
EMA/PE/0000184114
Submitted by Anonymous (not verified) on 14 July 2026 - 13:28
EMA/PE/0000184114
EMA/PE/0000242080
Submitted by Anonymous (not verified) on 14 July 2026 - 13:25
EMA/PE/0000242080
Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 14 July 2026 - 13:23
Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised
EMA/PE/0000221389
Submitted by Anonymous (not verified) on 14 July 2026 - 13:22
EMA/PE/0000221389
Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 14 July 2026 - 13:15
Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 3, Status: Authorised
Changing the labelling and package leaflet (Article 61(3) notifications)
Submitted by Anonymous (not verified) on 14 July 2026 - 13:00
Changing the labelling and package leaflet (Article 61(3) notifications)
EMA/PE/0000232449
Submitted by Anonymous (not verified) on 14 July 2026 - 12:45
EMA/PE/0000232449